Literature DB >> 28757327

Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.

Anna Parievsky1, Cindy Moore2, Talia Kamdjou1, Carlos Cepeda1, Charles K Meshul3, Michael S Levine4.   

Abstract

Huntington's disease (HD) is a fatal genetic disorder characterized by cell death of medium-sized spiny neurons (MSNs) in the striatum, traditionally attributed to excessive glutamate inputs and/or receptor sensitivity. While changes in corticostriatal projections have typically been studied in mouse models of HD, morphological and functional alterations in thalamostriatal projections have received less attention. In this study, an adeno-associated virus expressing channelrhodopsin-2 under the calcium/calmodulin-dependent protein kinase IIα promoter was injected into the sensorimotor cortex or the thalamic centromedian-parafascicular nuclear complex in the R6/2 mouse model of HD, to permit selective activation of corticostriatal or thalamostriatal projections, respectively. In symptomatic R6/2 mice, peak amplitudes and areas of corticostriatal glutamate AMPA and NMDA receptor-mediated responses were reduced. In contrast, although peak amplitudes of AMPA and NMDA receptor-mediated thalamostriatal responses also were reduced, the areas remained unchanged due to an increase in response decay times. Blockade of glutamate reuptake further increased response areas and slowed rise and decay times of NMDA responses. These effects appeared more pronounced at thalamostriatal synapses of R6/2 mice, suggesting increased activation of extrasynaptic NMDA receptors. In addition, the probability of glutamate release was higher at thalamostriatal than corticostriatal synapses, particularly in R6/2 mice. Morphological studies indicated that the density of all excitatory synaptic contacts onto MSNs was reduced, which matches the basic electrophysiological findings of reduced amplitudes. There was a consistent reduction in the area of spines but little change in presynaptic terminal size, indicating that the postsynaptic spine may be more significantly affected than presynaptic terminals. These results highlight the significant and differential contribution of the thalamostriatal projection to glutamate excitotoxicity in HD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Electron microscopy; Huntington's disease; Medium-sized spiny neurons; Optogenetics; R6/2; Thalamus

Mesh:

Substances:

Year:  2017        PMID: 28757327      PMCID: PMC5675804          DOI: 10.1016/j.nbd.2017.07.020

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  74 in total

1.  Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.

Authors:  B Nicniocaill; B Haraldsson; O Hansson; W T O'Connor; P Brundin
Journal:  Eur J Neurosci       Date:  2001-01       Impact factor: 3.386

2.  The long-term effect of tetrabenazine in the management of Huntington disease.

Authors:  Alfonso Fasano; Federica Cadeddu; Arianna Guidubaldi; Carla Piano; Francesco Soleti; Paola Zinzi; Anna Rita Bentivoglio
Journal:  Clin Neuropharmacol       Date:  2008 Nov-Dec       Impact factor: 1.592

3.  Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum.

Authors:  H W Berendse; H J Groenewegen
Journal:  J Comp Neurol       Date:  1990-09-08       Impact factor: 3.215

4.  Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.

Authors:  J C Liévens; B Woodman; A Mahal; O Spasic-Boscovic; D Samuel; L Kerkerian-Le Goff; G P Bates
Journal:  Neurobiol Dis       Date:  2001-10       Impact factor: 5.996

Review 5.  Excitotoxic injury of the neostriatum: a model for Huntington's disease.

Authors:  M DiFiglia
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

6.  Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release.

Authors:  He Li; Travis Wyman; Zhao-Xue Yu; Shi-Hua Li; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2003-08-15       Impact factor: 6.150

7.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Authors:  B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

8.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

9.  Efferent connections of the centromedian and parafascicular thalamic nuclei in the squirrel monkey: a PHA-L study of subcortical projections.

Authors:  A F Sadikot; A Parent; C François
Journal:  J Comp Neurol       Date:  1992-01-08       Impact factor: 3.215

10.  Cholinergic interneurons in the Q140 knockin mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input.

Authors:  Yun-Ping Deng; Anton Reiner
Journal:  J Comp Neurol       Date:  2016-06-06       Impact factor: 3.215

View more
  20 in total

1.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

2.  Single Synapse Indicators of Impaired Glutamate Clearance Derived from Fast iGlu u Imaging of Cortical Afferents in the Striatum of Normal and Huntington (Q175) Mice.

Authors:  Anton Dvorzhak; Nordine Helassa; Katalin Török; Dietmar Schmitz; Rosemarie Grantyn
Journal:  J Neurosci       Date:  2019-02-28       Impact factor: 6.167

Review 3.  Developmental origins of cortical hyperexcitability in Huntington's disease: Review and new observations.

Authors:  Carlos Cepeda; Katerina D Oikonomou; Damian Cummings; Joshua Barry; Vannah-Wila Yazon; Dickson T Chen; Janelle Asai; Christopher K Williams; Harry V Vinters
Journal:  J Neurosci Res       Date:  2019-07-28       Impact factor: 4.164

Review 4.  The Tiny Drosophila Melanogaster for the Biggest Answers in Huntington's Disease.

Authors:  Abraham Rosas-Arellano; Argel Estrada-Mondragón; Ricardo Piña; Carola A Mantellero; Maite A Castro
Journal:  Int J Mol Sci       Date:  2018-08-14       Impact factor: 5.923

Review 5.  Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

Authors:  George V Rebec
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

6.  Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Daniel Castro; Kenia Portillo-Ortiz; Katrina Jang; Michael Nedjat-Haiem; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2018-10-11       Impact factor: 5.243

Review 7.  Disrupted striatal neuron inputs and outputs in Huntington's disease.

Authors:  Anton Reiner; Yun-Ping Deng
Journal:  CNS Neurosci Ther       Date:  2018-04       Impact factor: 5.243

8.  Striatal network modeling in Huntington's Disease.

Authors:  Adam Ponzi; Scott J Barton; Kendra D Bunner; Claudia Rangel-Barajas; Emily S Zhang; Benjamin R Miller; George V Rebec; James Kozloski
Journal:  PLoS Comput Biol       Date:  2020-04-17       Impact factor: 4.475

9.  Striatal Direct and Indirect Pathway Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease.

Authors:  Joshua Barry; Garnik Akopian; Carlos Cepeda; Michael S Levine
Journal:  J Neurosci       Date:  2018-04-24       Impact factor: 6.167

10.  Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.

Authors:  Marja D Sepers; Amy Smith-Dijak; Jeff LeDue; Karolina Kolodziejczyk; Ken Mackie; Lynn A Raymond
Journal:  J Neurosci       Date:  2017-11-30       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.